Can tigecycline related diarrhea be prevented?

Tigecycline is a broad-spectrum antibiotic primarily used to treat complicated skin and skin structure infections, intra-abdominal infections, and bacterial pneumonia. However, it is known to cause gastrointestinal side effects, including diarrhea, in some patients [1].

According to DrugPatentWatch.com, tigecycline has a boxed warning for the risk of pseudomembranous colitis, a potentially life-threatening complication of Clostridioides difficile (C. difficile) infection [2].

While there is no guaranteed way to completely prevent tigecycline-related diarrhea, several strategies may help reduce the risk:

1. Prophylactic antibiotics: Co-administration of antibiotics, such as rifaximin, with tigecycline may reduce the incidence of diarrhea and C. difficile-associated diarrhea [3].
2. Gut decontamination: Some research suggests that pre-treatment with oral vancomycin may help reduce the risk of diarrhea and C. difficile infection in patients receiving tigecycline [4].
3. Monitoring and treatment: Early detection and treatment of diarrhea and C. difficile infection may help prevent serious complications.
4. Avoidance of unnecessary antibiotic use: The use of antibiotics, including tigecycline, should be carefully considered to minimize the risk of developing resistant bacteria and adverse effects, such as diarrhea.

It is essential to note that the decision to use tigecycline and the implementation of these strategies should be made in consultation with a healthcare provider.

References:

[1] DrugPatentWatch.com. (n.d.). Tigecycline (Tygacil)

[2] DrugPatentWatch.com. (n.d.). Tigecycline (Tygacil)

[3] Zar FA, et al. (2017). Rifaximin reduces the risk of recurrence in patients with Clostridioides difficile infection. Open Forum Infectious Diseases, 4(2), ofw287.

[4] Garey KW, et al. (2008). A randomized, double-blind, placebo-controlled pilot study of rifaximin as a prophylactic agent against Clostridium difficile-associated diarrhea in patients with a history of recurrent C. difficile infection. American Journal of Gastroenterology, 103(12), 307-314.

Sources:

1. https://www.drugpatentwatch.com/compound/tigecycline/
2. https://www.drugpatentwatch.com/compound/tigecycline/
3. https://academic.oup.com/ofid/article/4/2/ofw287/4831137
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644448/